1
|
García-Aranda M, Téllez T, McKenna L, Redondo M. Neurokinin-1 Receptor (NK-1R) Antagonists as a New Strategy to Overcome Cancer Resistance. Cancers (Basel) 2022; 14:cancers14092255. [PMID: 35565383 PMCID: PMC9102068 DOI: 10.3390/cancers14092255] [Citation(s) in RCA: 9] [Impact Index Per Article: 4.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/16/2022] [Revised: 04/22/2022] [Accepted: 04/28/2022] [Indexed: 12/25/2022] Open
Abstract
Nowadays, the identification of new therapeutic targets that allow for the development of treatments, which as monotherapy, or in combination with other existing treatments can contribute to improve response rates, prognosis and survival of oncologic patients, is a priority to optimize healthcare within sustainable health systems. Recent studies have demonstrated the role of Substance P (SP) and its preferred receptor, Neurokinin 1 Receptor (NK-1R), in human cancer and the potential antitumor activity of NK-1R antagonists as an anticancer treatment. In this review, we outline the relevant studies published to date regarding the SP/NK-1R complex as a key player in human cancer and also evaluate if the repurposing of already marketed NK-1R antagonists may be useful in the development of new treatment strategies to overcome cancer resistance.
Collapse
Affiliation(s)
- Marilina García-Aranda
- Research and Innovation Unit, Hospital Costa del Sol, Autovía A-7, km 187, 29603 Marbella, Spain; (M.G.-A.); (L.M.)
- Instituto de Investigación Biomédica de Málaga (IBIMA), C/Dr. Miguel Díaz Recio, 28, 29010 Málaga, Spain
- Red de Investigación en Servicios de Salud en Enfermedades Crónicas (REDISSEC) and Red de Investigación en Cronicidad, Atención Primaria y Promoción de la Salud (RICAPPS), Instituto de Investigación Biomédica de Málaga (IBIMA), 29010 Málaga, Spain;
- Surgical Specialties, Biochemistry and Immunology Department, Faculty of Medicine, University of Málaga, 29010 Málaga, Spain
| | - Teresa Téllez
- Red de Investigación en Servicios de Salud en Enfermedades Crónicas (REDISSEC) and Red de Investigación en Cronicidad, Atención Primaria y Promoción de la Salud (RICAPPS), Instituto de Investigación Biomédica de Málaga (IBIMA), 29010 Málaga, Spain;
- Surgical Specialties, Biochemistry and Immunology Department, Faculty of Medicine, University of Málaga, 29010 Málaga, Spain
| | - Lauraine McKenna
- Research and Innovation Unit, Hospital Costa del Sol, Autovía A-7, km 187, 29603 Marbella, Spain; (M.G.-A.); (L.M.)
| | - Maximino Redondo
- Research and Innovation Unit, Hospital Costa del Sol, Autovía A-7, km 187, 29603 Marbella, Spain; (M.G.-A.); (L.M.)
- Instituto de Investigación Biomédica de Málaga (IBIMA), C/Dr. Miguel Díaz Recio, 28, 29010 Málaga, Spain
- Red de Investigación en Servicios de Salud en Enfermedades Crónicas (REDISSEC) and Red de Investigación en Cronicidad, Atención Primaria y Promoción de la Salud (RICAPPS), Instituto de Investigación Biomédica de Málaga (IBIMA), 29010 Málaga, Spain;
- Surgical Specialties, Biochemistry and Immunology Department, Faculty of Medicine, University of Málaga, 29010 Málaga, Spain
- Correspondence:
| |
Collapse
|
2
|
De Logu F, Patacchini R, Fontana G, Geppetti P. TRP functions in the broncho-pulmonary system. Semin Immunopathol 2016; 38:321-9. [PMID: 27083925 DOI: 10.1007/s00281-016-0557-1] [Citation(s) in RCA: 29] [Impact Index Per Article: 3.6] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/27/2015] [Accepted: 02/09/2016] [Indexed: 12/23/2022]
Abstract
The current understanding of the role of transient receptor potential (TRP) channels in the airways and lung was initially based on the localization of a series of such channels in a subset of sensory nerve fibers of the respiratory tract. Soon after, TRP channel expression and function have been identified in respiratory nonneuronal cells. In these two locations, TRPs regulate physiological processes aimed at integrating different stimuli to maintain homeostasis and to react to harmful agents and tissue injury by building up inflammatory responses and repair processes. There is no doubt that TRPs localized in the sensory network contribute to airway neurogenic inflammation, and emerging evidence underlines the role of nonneuronal TRPs in orchestrating inflammation and repair in the respiratory tract. However, recent basic and clinical studies have offered clues regarding the contribution of neuronal and nonneuronal TRPs in the mechanism of asthma, chronic obstructive pulmonary disease, idiopathic pulmonary fibrosis, cough, and other respiratory diseases.
Collapse
Affiliation(s)
- Francesco De Logu
- Clinical Pharmacology Unit, Department of Health Sciences, University of Florence, Viale Pieraccini, 6, 50139, Florence, Italy
| | - Riccardo Patacchini
- Clinical Pharmacology Unit, Department of Health Sciences, University of Florence, Viale Pieraccini, 6, 50139, Florence, Italy
- Chiesi Farmaceutici S.p.A, Parma, Italy
| | - Giovanni Fontana
- Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy
| | - Pierangelo Geppetti
- Clinical Pharmacology Unit, Department of Health Sciences, University of Florence, Viale Pieraccini, 6, 50139, Florence, Italy.
| |
Collapse
|
3
|
Grobman M, Graham A, Outi H, Dodam JR, Reinero CR. Chronic neurokinin-1 receptor antagonism fails to ameliorate clinical signs, airway hyper-responsiveness or airway eosinophilia in an experimental model of feline asthma. J Feline Med Surg 2016; 18:273-9. [PMID: 25964466 PMCID: PMC11112248 DOI: 10.1177/1098612x15581406] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
OBJECTIVES Feline allergic asthma is a common chronic lower airway disease characterized by clinical signs attributed to eosinophilic inflammation, airway hyper-responsiveness (AHR) and airway remodeling. Tachykinins released from sensory nerves and immune cells bind neurokinin-1 (NK-1) receptors in the lung. The resultant neurogenic airway inflammation has been implicated in asthma pathogenesis. In mouse models and spontaneous human asthma, NK receptor antagonists reduce bronchospasm and inflammation. We hypothesized that chronic administration of maropitant, an NK-1 receptor antagonist, would decrease clinical signs of asthma, AHR and eosinophilic inflammation in experimentally asthmatic cats. METHODS Cats (n = 6) induced to have asthma using Bermuda grass allergen (BGA) were enrolled in a randomized, prospective, placebo-controlled crossover design study. Cats received either oral maropitant (2 mg/kg) or placebo q48h for 4 weeks; following a 2 week washout, cats were crossed-over to the alternate treatment. Study endpoints included subjective clinical scoring systems after BGA challenge, ventilator-acquired pulmonary mechanics to assess AHR after bronchoprovocation with methacholine, and collection of bronchoalveolar lavage fluid to quantify airway eosinophilia. Statistical analysis was performed using a Mann-Whitney rank sum test with P <0.05 considered significant. RESULTS Administration of maropitant for 1 month in experimentally asthmatic cats produced no significant difference in clinical scoring scheme (P = 0.589 and P = 1.0), AHR (P = 0.818) or airway eosinophilia (P = 0.669) compared with placebo. CONCLUSIONS AND RELEVANCE Chronic administration of maropitant was ineffective at blunting clinical signs, AHR and airway eosinophilia in experimental feline asthma and thus cannot be recommended as a novel treatment for this disorder.
Collapse
Affiliation(s)
- Megan Grobman
- Department of Veterinary Medicine and Surgery, College of Veterinary Medicine, University of Missouri, Columbia, MO, USA
| | - Amber Graham
- Department of Veterinary Medicine and Surgery, College of Veterinary Medicine, University of Missouri, Columbia, MO, USA
| | - Hilton Outi
- Department of Veterinary Medicine and Surgery, College of Veterinary Medicine, University of Missouri, Columbia, MO, USA
| | - John R Dodam
- Department of Veterinary Medicine and Surgery, College of Veterinary Medicine, University of Missouri, Columbia, MO, USA
| | - Carol R Reinero
- Department of Veterinary Medicine and Surgery, College of Veterinary Medicine, University of Missouri, Columbia, MO, USA
| |
Collapse
|
4
|
Grobman M, Krumme S, Outi H, Dodam JR, Reinero CR. Acute neurokinin-1 receptor antagonism fails to dampen airflow limitation or airway eosinophilia in an experimental model of feline asthma. J Feline Med Surg 2016; 18:176-81. [PMID: 25964467 PMCID: PMC11149008 DOI: 10.1177/1098612x15581405] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
Abstract
OBJECTIVES Feline allergic asthma is a chronic inflammatory disorder of the lower airways that may manifest with acute, life-threatening clinical signs. Tachykinins released from sensory nerves and immune cells binding neurokinin (NK)-1, NK-2 and NK-3 receptors have been implicated in asthma pathogenesis. Maropitant, an NK-1 receptor antagonist, blocks neuroimmune pathways and may be a viable treatment option for cats in asthmatic crisis. Using an experimental chronic allergic feline asthma model, we hypothesized that a single dose of maropitant given immediately after allergen challenge would blunt clinical signs, airway hyperresponsiveness (AHR) and airway eosinophilia. METHODS Cats (n = 7) induced to have an asthmatic phenotype using Bermuda grass allergen (BGA) were enrolled in a prospective, placebo-controlled crossover design study. Cats randomly received maropitant (2 mg/kg SC) or placebo (saline SC) immediately post-BGA challenge, followed 12 h later by pulmonary mechanics testing and measurement of airway eosinophils. After a 2 week washout, cats were crossed-over to the alternate treatment. Study endpoints included subjective clinical scoring systems post-BGA challenge, ventilator-acquired pulmonary mechanics to assess AHR after bronchoprovocation with methacholine and collection of bronchoalveolar lavage fluid to quantify airway eosinophilia. Data were analyzed using a Mann-Whitney rank sum test with P <0.05 considered significant. RESULTS A single injection of maropitant failed to diminish clinical composite score (P = 0.902), visual analogue scale scoring (P = 0.710), AHR (P = 0.456) or airway eosinophilia (P = 0.165) compared with placebo. CONCLUSIONS AND RELEVANCE A single injection of maropitant given immediately post-allergen challenge was ineffective at blunting clinical signs, AHR and airway eosinophilia, and cannot be recommended as treatment for feline status asthmaticus.
Collapse
Affiliation(s)
- Megan Grobman
- Department of Veterinary Medicine and Surgery, College of Veterinary Medicine, University of Missouri, Columbia, MO, USA
| | - Stacy Krumme
- Department of Veterinary Medicine and Surgery, College of Veterinary Medicine, University of Missouri, Columbia, MO, USA
| | - Hilton Outi
- Department of Veterinary Medicine and Surgery, College of Veterinary Medicine, University of Missouri, Columbia, MO, USA
| | - John R Dodam
- Department of Veterinary Medicine and Surgery, College of Veterinary Medicine, University of Missouri, Columbia, MO, USA
| | - Carol R Reinero
- Department of Veterinary Medicine and Surgery, College of Veterinary Medicine, University of Missouri, Columbia, MO, USA
| |
Collapse
|
5
|
Wu Z, Graybill TL, Zeng X, Platchek M, Zhang J, Bodmer VQ, Wisnoski DD, Deng J, Coppo FT, Yao G, Tamburino A, Scavello G, Franklin GJ, Mataruse S, Bedard KL, Ding Y, Chai J, Summerfield J, Centrella PA, Messer JA, Pope AJ, Israel DI. Cell-Based Selection Expands the Utility of DNA-Encoded Small-Molecule Library Technology to Cell Surface Drug Targets: Identification of Novel Antagonists of the NK3 Tachykinin Receptor. ACS COMBINATORIAL SCIENCE 2015; 17:722-31. [PMID: 26562224 DOI: 10.1021/acscombsci.5b00124] [Citation(s) in RCA: 95] [Impact Index Per Article: 10.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
Abstract
DNA-encoded small-molecule library technology has recently emerged as a new paradigm for identifying ligands against drug targets. To date, this technology has been used with soluble protein targets that are produced and used in a purified state. Here, we describe a cell-based method for identifying small-molecule ligands from DNA-encoded libraries against integral membrane protein targets. We use this method to identify novel, potent, and specific inhibitors of NK3, a member of the tachykinin family of G-protein coupled receptors (GPCRs). The method is simple and broadly applicable to other GPCRs and integral membrane proteins. We have extended the application of DNA-encoded library technology to membrane-associated targets and demonstrate the feasibility of selecting DNA-tagged, small-molecule ligands from complex combinatorial libraries against targets in a heterogeneous milieu, such as the surface of a cell.
Collapse
Affiliation(s)
- Zining Wu
- Molecular
Discovery Research, GlaxoSmithKline, Collegeville, Pennsylvania 19426, United States
| | - Todd L. Graybill
- Molecular
Discovery Research, GlaxoSmithKline, Collegeville, Pennsylvania 19426, United States
| | - Xin Zeng
- Molecular
Discovery Research, GlaxoSmithKline, Collegeville, Pennsylvania 19426, United States
| | - Michael Platchek
- Molecular
Discovery Research, GlaxoSmithKline, Collegeville, Pennsylvania 19426, United States
| | - Jean Zhang
- Molecular
Discovery Research, GlaxoSmithKline, Waltham, Massachusetts 02451, United States
| | - Vera Q. Bodmer
- Molecular
Discovery Research, GlaxoSmithKline, Collegeville, Pennsylvania 19426, United States
| | - David D. Wisnoski
- Molecular
Discovery Research, GlaxoSmithKline, Collegeville, Pennsylvania 19426, United States
| | - Jianghe Deng
- Molecular
Discovery Research, GlaxoSmithKline, Collegeville, Pennsylvania 19426, United States
| | - Frank T. Coppo
- Molecular
Discovery Research, GlaxoSmithKline, Collegeville, Pennsylvania 19426, United States
| | - Gang Yao
- Molecular
Discovery Research, GlaxoSmithKline, Waltham, Massachusetts 02451, United States
| | - Alex Tamburino
- Molecular
Discovery Research, GlaxoSmithKline, Waltham, Massachusetts 02451, United States
| | - Genaro Scavello
- Molecular
Discovery Research, GlaxoSmithKline, Collegeville, Pennsylvania 19426, United States
| | - G. Joseph Franklin
- Molecular
Discovery Research, GlaxoSmithKline, Waltham, Massachusetts 02451, United States
| | - Sibongile Mataruse
- Molecular
Discovery Research, GlaxoSmithKline, Waltham, Massachusetts 02451, United States
| | - Katie L. Bedard
- Molecular
Discovery Research, GlaxoSmithKline, Waltham, Massachusetts 02451, United States
| | - Yun Ding
- Molecular
Discovery Research, GlaxoSmithKline, Waltham, Massachusetts 02451, United States
| | - Jing Chai
- Molecular
Discovery Research, GlaxoSmithKline, Waltham, Massachusetts 02451, United States
| | - Jennifer Summerfield
- Molecular
Discovery Research, GlaxoSmithKline, Waltham, Massachusetts 02451, United States
| | - Paolo A. Centrella
- Molecular
Discovery Research, GlaxoSmithKline, Waltham, Massachusetts 02451, United States
| | - Jeffrey A. Messer
- Molecular
Discovery Research, GlaxoSmithKline, Waltham, Massachusetts 02451, United States
| | - Andrew J. Pope
- Molecular
Discovery Research, GlaxoSmithKline, Collegeville, Pennsylvania 19426, United States
| | - David I. Israel
- Molecular
Discovery Research, GlaxoSmithKline, Waltham, Massachusetts 02451, United States
| |
Collapse
|
6
|
Refractoriness to exercise challenge: a review of the mechanisms old and new. Immunol Allergy Clin North Am 2013; 33:329-45, viii. [PMID: 23830128 DOI: 10.1016/j.iac.2013.02.004] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
Abstract
This article discusses the available literature on refractoriness in exercise-induced bronchoconstriction, namely, a decrease in airway responsiveness with repeated exercise challenges. The mechanisms of this naturally occurring protective feature is unknown. Reviewing previous studies together with findings in more recent studies, the authors propose desensitization of the G protein-coupled cysteinyl leukotriene receptor1 as the mechanism of refractoriness and that this desensitization occurs as a result of interplay between leukotrienes and prostaglandins.
Collapse
|
7
|
Nassini R, Pedretti P, Moretto N, Fusi C, Carnini C, Facchinetti F, Viscomi AR, Pisano AR, Stokesberry S, Brunmark C, Svitacheva N, McGarvey L, Patacchini R, Damholt AB, Geppetti P, Materazzi S. Transient receptor potential ankyrin 1 channel localized to non-neuronal airway cells promotes non-neurogenic inflammation. PLoS One 2012; 7:e42454. [PMID: 22905134 PMCID: PMC3419223 DOI: 10.1371/journal.pone.0042454] [Citation(s) in RCA: 176] [Impact Index Per Article: 14.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/13/2012] [Accepted: 07/06/2012] [Indexed: 02/06/2023] Open
Abstract
Background The transient receptor potential ankyrin 1 (TRPA1) channel, localized to airway sensory nerves, has been proposed to mediate airway inflammation evoked by allergen and cigarette smoke (CS) in rodents, via a neurogenic mechanism. However the limited clinical evidence for the role of neurogenic inflammation in asthma or chronic obstructive pulmonary disease raises an alternative possibility that airway inflammation is promoted by non-neuronal TRPA1. Methodology/Principal Findings By using Real-Time PCR and calcium imaging, we found that cultured human airway cells, including fibroblasts, epithelial and smooth muscle cells express functional TRPA1 channels. By using immunohistochemistry, TRPA1 staining was observed in airway epithelial and smooth muscle cells in sections taken from human airways and lung, and from airways and lung of wild-type, but not TRPA1-deficient mice. In cultured human airway epithelial and smooth muscle cells and fibroblasts, acrolein and CS extract evoked IL-8 release, a response selectively reduced by TRPA1 antagonists. Capsaicin, agonist of the transient receptor potential vanilloid 1 (TRPV1), a channel co-expressed with TRPA1 by airway sensory nerves, and acrolein or CS (TRPA1 agonists), or the neuropeptide substance P (SP), which is released from sensory nerve terminals by capsaicin, acrolein or CS), produced neurogenic inflammation in mouse airways. However, only acrolein and CS, but not capsaicin or SP, released the keratinocyte chemoattractant (CXCL-1/KC, IL-8 analogue) in bronchoalveolar lavage (BAL) fluid of wild-type mice. This effect of TRPA1 agonists was attenuated by TRPA1 antagonism or in TRPA1-deficient mice, but not by pharmacological ablation of sensory nerves. Conclusions Our results demonstrate that, although either TRPV1 or TRPA1 activation causes airway neurogenic inflammation, solely TRPA1 activation orchestrates an additional inflammatory response which is not neurogenic. This finding suggests that non-neuronal TRPA1 in the airways is functional and potentially capable of contributing to inflammatory airway diseases.
Collapse
Affiliation(s)
- Romina Nassini
- Department of Preclinical and Clinical Pharmacology, University of Florence, Florence, Italy
| | - Pamela Pedretti
- Department of Preclinical and Clinical Pharmacology, University of Florence, Florence, Italy
- Pharmacology Department, Chiesi Farmaceutici SpA, Parma, Italy
| | - Nadia Moretto
- Pharmacology Department, Chiesi Farmaceutici SpA, Parma, Italy
| | - Camilla Fusi
- Department of Preclinical and Clinical Pharmacology, University of Florence, Florence, Italy
| | - Chiara Carnini
- Pharmacology Department, Chiesi Farmaceutici SpA, Parma, Italy
| | | | | | | | - Susan Stokesberry
- Centre for Infection and Immunity, Queen's University Belfast, Belfast, United Kingdom
| | - Charlott Brunmark
- AstraZeneca Research & Development Innovative Medicines Respiratory & Inflammation, Mölndal, Sweden
- Truly Translational Sweden AB, Lund, Sweden
| | - Naila Svitacheva
- AstraZeneca Research & Development Innovative Medicines Respiratory & Inflammation, Mölndal, Sweden
- Disease Pharmacology LEO Pharma A/S, Ballerup, Denmark
| | - Lorcan McGarvey
- Centre for Infection and Immunity, Queen's University Belfast, Belfast, United Kingdom
| | | | - Anders B. Damholt
- AstraZeneca Research & Development Innovative Medicines Respiratory & Inflammation, Mölndal, Sweden
- Department of Biology, University of Copenhagen, Copenhagen, Denmark
| | - Pierangelo Geppetti
- Department of Preclinical and Clinical Pharmacology, University of Florence, Florence, Italy
- Headache Center, University of Florence, Florence, Italy
- * E-mail:
| | - Serena Materazzi
- Department of Preclinical and Clinical Pharmacology, University of Florence, Florence, Italy
| |
Collapse
|
8
|
Ramalho R, Soares R, Couto N, Moreira A. Tachykinin receptors antagonism for asthma: a systematic review. BMC Pulm Med 2011; 11:41. [PMID: 21810226 PMCID: PMC3163224 DOI: 10.1186/1471-2466-11-41] [Citation(s) in RCA: 42] [Impact Index Per Article: 3.2] [Reference Citation Analysis] [Abstract] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/25/2010] [Accepted: 08/02/2011] [Indexed: 11/10/2022] Open
Abstract
Background Tachykinins substance P, neurokinin A and neurokinin B seem to account for asthma pathophysiology by mediating neurogenic inflammation and several aspects of lung mechanics. These neuropeptides act mainly by their receptors NK1, NK2 and NK3, respectively which may be targets for new asthma therapy. Methods This review systematically examines randomized controlled trials evaluating the effect of tachykinins receptors antagonism on asthma. Symptoms, airway inflammation, lung function and airway inflammation were considered as outcomes. We searched the Cochrane Airways Group Specialized Register of Asthma Trials, Cochrane Database of Systematic Reviews, MEDLINE/PubMed and EMBASE. The search is as current as June 2010. Quality rating of included studies followed the Cochrane Collaboration and GRADE Profiler approaches. However, data were not pooled together due to different measures among the studies. Results Our systematic review showed the potential of NK receptor antagonist to decrease airway responsiveness and to improve lung function. However, effects on airway inflammation and asthma symptoms were poorly or not described. Conclusion The limited available evidence suggests that tachykinin receptors antagonists may decrease airway responsiveness and improve lung function in patients with asthma. Further large randomized trials are still required.
Collapse
Affiliation(s)
- Renata Ramalho
- Department of Immunology, Faculty of Medicine, University of Porto, Porto, Portugal.
| | | | | | | |
Collapse
|
9
|
Baraldi PG, Preti D, Materazzi S, Geppetti P. Transient receptor potential ankyrin 1 (TRPA1) channel as emerging target for novel analgesics and anti-inflammatory agents. J Med Chem 2010; 53:5085-107. [PMID: 20356305 DOI: 10.1021/jm100062h] [Citation(s) in RCA: 135] [Impact Index Per Article: 9.6] [Reference Citation Analysis] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/07/2023]
Affiliation(s)
- Pier Giovanni Baraldi
- Department of Pharmaceutical Sciences, Ferrara University, Via Fossato di Mortara 17-19, 44100 Ferrara, Italy.
| | | | | | | |
Collapse
|
10
|
Hydrogen sulfide promotes transient receptor potential vanilloid 1-mediated neurogenic inflammation in polymicrobial sepsis. Crit Care Med 2010; 38:619-28. [PMID: 19851090 DOI: 10.1097/ccm.0b013e3181c0df00] [Citation(s) in RCA: 54] [Impact Index Per Article: 3.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
Abstract
OBJECTIVE To investigate the interaction and involvement of hydrogen sulfide and transient receptor potential vanilloid type 1 in the pathogenesis of sepsis. Hydrogen sulfide has been demonstrated to be involved in many inflammatory states including sepsis. Its contribution in neurogenic inflammation has been suggested in normal airways and urinary bladder. However, whether endogenous hydrogen sulfide would induce transient receptor potential vanilloid type 1-mediated neurogenic inflammation in sepsis remains unknown. DESIGN Prospective, experimental study. SETTING Research laboratory. SUBJECT Male Swiss mice. INTERVENTIONS Mice were subjected to cecal ligation and puncture-induced sepsis and treated with transient receptor potential vanilloid type 1 antagonist capsazepine (15 mg/kg subcutaneous) 30 mins before cecal ligation and puncture. To investigate hydrogen sulfide-mediated neurogenic inflammation in sepsis, DL-propargylglycine (50 mg/kg intraperitoneal), an inhibitor of hydrogen sulfide formation was administrated 1 hr before or 1 hr after the induction of sepsis, whereas sodium hydrosulfide (10 mg/kg intraperitoneal), a hydrogen sulfide donor, was given at the same time as cecal ligation and puncture. Lung and liver myeloperoxidase activities, liver cystathionine-gamma-lyase activity, plasma hydrogen sulfide level, histopathological examination, and survival studies were determined after induction of sepsis. MEASUREMENTS AND MAIN RESULTS Capsazepine treatment attenuates significantly systemic inflammation and multiple organ damage caused by sepsis, and protects against sepsis-induced mortality. Similarly, administration of sodium hydrosulfide exacerbates but capsazepine reverses these deleterious effects. In the presence of DL-propargylglycine, capsazepine causes no significant changes to the attenuation of sepsis-associated systemic inflammation, multiple organ damage, and mortality. In addition, capsazepine has no effect on endogenous generation of hydrogen sulfide, suggesting that hydrogen sulfide is located upstream of transient receptor potential vanilloid type 1 activation, and may play a critical role in regulating the production and release of sensory neuropeptides in sepsis. CONCLUSIONS The present study shows that hydrogen sulfide induces systemic inflammation and multiple organ damage characteristic of sepsis via transient receptor potential vanilloid type 1-mediated neurogenic inflammation.
Collapse
|
11
|
Kichko TI, Reeh PW. TRPV1 controls acid- and heat-induced calcitonin gene-related peptide release and sensitization by bradykinin in the isolated mouse trachea. Eur J Neurosci 2009; 29:1896-904. [PMID: 19473241 DOI: 10.1111/j.1460-9568.2009.06747.x] [Citation(s) in RCA: 35] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/01/2022]
Abstract
Chronic cough derives from inflammatory hypersensitivity of tracheobronchial nerve endings, most of which express the polymodal capsaicin receptor-channel transient receptor potential vanilloid (TRPV) type 1 and the secretory neuropeptide calcitonin gene-related peptide (CGRP). An isolated mouse trachea preparation was established to measure chemically and thermally stimulated CGRP release as an index for sensory transduction of potential cough-inducing stimuli. TRPV1 knockout mice were employed to assess the TRPV1 contribution to tracheal responsiveness and sensitization. Graded heat-induced CGRP release depended entirely on extracellular calcium and partly on TRPV1; knockout mice showed 60% less CGRP release at 45 degrees C (for 5 min) than wild-types. This heat response was facilitated by the TRPV1 agonist ethanol and the TRPV1-3 agonist 2-aminoethoxydiphenyl borate, effects that were reduced or absent in TRPV1(-/-), respectively. The TRPV1 antagonists ruthenium red and N-(4-t-butylphenyl)-4-(3-chloropyridin-2-yl) tetrahydropyrazine-1(2H)-carboxamide were ineffective on the basal heat response. A step increase of temperature from 22 to 40 degrees C caused a TRPV1-independent CGRP release that was doubled by bradykinin in wild-types but not TRPV1(-/-). Proton stimulation resulted in a bell-shaped concentration-response curve with threshold at pH 6.7 and a maximum at pH 5.7; responses were greatly reduced but not abolished in TRPV1(-/-). Coadministration of amiloride (30 microm), the blocker of acid-sensing ion channels, was ineffective in both TRPV1 genotypes. The data suggest that tracheal acid sensing mainly involves TRPV1 but not acid-sensing ion channels, whereas noxious heat responsiveness partly depends and (inflammatory) sensitization to heat largely depends on the capsaicin receptor in tracheal nerve endings. Lowering of their heat threshold to near body temperature may sustain hypersensitivity and neurogenic inflammation of the upper airways.
Collapse
Affiliation(s)
- Tatjana I Kichko
- Department of Physiology and Pathophysiology, University of Erlangen-Nuremberg, Erlangen, Germany.
| | | |
Collapse
|
12
|
Veres TZ, Rochlitzer S, Braun A. The role of neuro-immune cross-talk in the regulation of inflammation and remodelling in asthma. Pharmacol Ther 2009; 122:203-14. [PMID: 19292991 DOI: 10.1016/j.pharmthera.2009.02.007] [Citation(s) in RCA: 52] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/19/2009] [Accepted: 02/23/2009] [Indexed: 12/22/2022]
Abstract
Despite recent advances in the development of anti-asthmatic medication, asthma continues to be a major health problem worldwide. The symptoms of asthmatic patients include wheezing, chest tightness, cough and shortness of breath, which, together with airway hyperresponiveness, previously have been attributed to a dysfunction of airway nerves. However, research in the last two decades identified Th2-sensitization and the subsequent allergic reaction to innocuous environmental antigens as a basic immunological mechanism leading to chronic airway inflammation. Recent evidence suggests that the development of allergic asthma is influenced by events and circumstances in early childhood and even in utero. Allergen, ozone or stress exposure, as well as RSV infection in early life could be able to induce irreversible changes in the developing epithelial-mesenchymal trophic unit of the airways. The co-existence of chronic inflammation and neural dysfunction have recently drawn attention to the involvement of interaction pathways between the nervous and the immune system in the airways. Intensive basic research has accumulated morphological as well as functional evidence for the interaction between nerves and immune cells. Neuropeptides and neurotrophins have come into focus of attention as the key mediators of neuro-immune interactions, which lead to the development of several pharmacological compounds specifically targeting these molecules. This review will integrate our current knowledge on the involvement of neuro-immune pathways in asthma on the cellular and molecular level. It will summarize the results of pharmacological studies addressing the potential of neuropeptides and neurotrophins as novel therapeutic targets in asthma.
Collapse
Affiliation(s)
- Tibor Z Veres
- Department of Immunology, Allergology and Immunotoxicology, Fraunhofer Institute of Toxicology and Experimental Medicine, Hannover, Germany
| | | | | |
Collapse
|
13
|
Nardi A, Demnitz J, Garcia ML, Polosa R. Potassium channels as drug targets for therapeutic intervention in respiratory diseases. Expert Opin Ther Pat 2008. [DOI: 10.1517/13543770802553798] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/31/2022]
|
14
|
Andrè E, Campi B, Materazzi S, Trevisani M, Amadesi S, Massi D, Creminon C, Vaksman N, Nassini R, Civelli M, Baraldi PG, Poole DP, Bunnett NW, Geppetti P, Patacchini R. Cigarette smoke-induced neurogenic inflammation is mediated by alpha,beta-unsaturated aldehydes and the TRPA1 receptor in rodents. J Clin Invest 2008; 118:2574-82. [PMID: 18568077 PMCID: PMC2430498 DOI: 10.1172/jci34886] [Citation(s) in RCA: 193] [Impact Index Per Article: 12.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/27/2007] [Accepted: 04/23/2008] [Indexed: 01/21/2023] Open
Abstract
Cigarette smoke (CS) inhalation causes an early inflammatory response in rodent airways by stimulating capsaicin-sensitive sensory neurons that express transient receptor potential cation channel, subfamily V, member 1 (TRPV1) through an unknown mechanism that does not involve TRPV1. We hypothesized that 2 alpha,beta-unsaturated aldehydes present in CS, crotonaldehyde and acrolein, induce neurogenic inflammation by stimulating TRPA1, an excitatory ion channel coexpressed with TRPV1 on capsaicin-sensitive nociceptors. We found that CS aqueous extract (CSE), crotonaldehyde, and acrolein mobilized Ca2+ in cultured guinea pig jugular ganglia neurons and promoted contraction of isolated guinea pig bronchi. These responses were abolished by a TRPA1-selective antagonist and by the aldehyde scavenger glutathione but not by the TRPV1 antagonist capsazepine or by ROS scavengers. Treatment with CSE or aldehydes increased Ca2+ influx in TRPA1-transfected cells, but not in control HEK293 cells, and promoted neuropeptide release from isolated guinea pig airway tissue. Furthermore, the effect of CSE and aldehydes on Ca2+ influx in dorsal root ganglion neurons was abolished in TRPA1-deficient mice. These data identify alpha,beta-unsaturated aldehydes as the main causative agents in CS that via TRPA1 stimulation mediate airway neurogenic inflammation and suggest a role for TRPA1 in the pathogenesis of CS-induced diseases.
Collapse
Affiliation(s)
- Eunice Andrè
- Center of Excellence for the Study of Inflammation, University of Ferrara, Ferrara, Italy.
Clinical Pharmacology Unit, Department of Critical Care Medicine and Surgery, University of Florence, Florence, Italy.
Departments of Physiology and Surgery, UCSF, San Francisco, California, USA.
Department of Human Pathology and Oncology, University of Florence, Florence, Italy.
CEA, Institut de Biologie et Technologies de Saclay (iBiTec-S), Service de pharmacologie et d'immuno analyse (SPI), Gif sur Yvette, France.
Pharmacology Department, Chiesi Pharmaceuticals, Parma, Italy.
Department of Pharmaceutical Chemistry, University of Ferrara, Ferrara, Italy
| | - Barbara Campi
- Center of Excellence for the Study of Inflammation, University of Ferrara, Ferrara, Italy.
Clinical Pharmacology Unit, Department of Critical Care Medicine and Surgery, University of Florence, Florence, Italy.
Departments of Physiology and Surgery, UCSF, San Francisco, California, USA.
Department of Human Pathology and Oncology, University of Florence, Florence, Italy.
CEA, Institut de Biologie et Technologies de Saclay (iBiTec-S), Service de pharmacologie et d'immuno analyse (SPI), Gif sur Yvette, France.
Pharmacology Department, Chiesi Pharmaceuticals, Parma, Italy.
Department of Pharmaceutical Chemistry, University of Ferrara, Ferrara, Italy
| | - Serena Materazzi
- Center of Excellence for the Study of Inflammation, University of Ferrara, Ferrara, Italy.
Clinical Pharmacology Unit, Department of Critical Care Medicine and Surgery, University of Florence, Florence, Italy.
Departments of Physiology and Surgery, UCSF, San Francisco, California, USA.
Department of Human Pathology and Oncology, University of Florence, Florence, Italy.
CEA, Institut de Biologie et Technologies de Saclay (iBiTec-S), Service de pharmacologie et d'immuno analyse (SPI), Gif sur Yvette, France.
Pharmacology Department, Chiesi Pharmaceuticals, Parma, Italy.
Department of Pharmaceutical Chemistry, University of Ferrara, Ferrara, Italy
| | - Marcello Trevisani
- Center of Excellence for the Study of Inflammation, University of Ferrara, Ferrara, Italy.
Clinical Pharmacology Unit, Department of Critical Care Medicine and Surgery, University of Florence, Florence, Italy.
Departments of Physiology and Surgery, UCSF, San Francisco, California, USA.
Department of Human Pathology and Oncology, University of Florence, Florence, Italy.
CEA, Institut de Biologie et Technologies de Saclay (iBiTec-S), Service de pharmacologie et d'immuno analyse (SPI), Gif sur Yvette, France.
Pharmacology Department, Chiesi Pharmaceuticals, Parma, Italy.
Department of Pharmaceutical Chemistry, University of Ferrara, Ferrara, Italy
| | - Silvia Amadesi
- Center of Excellence for the Study of Inflammation, University of Ferrara, Ferrara, Italy.
Clinical Pharmacology Unit, Department of Critical Care Medicine and Surgery, University of Florence, Florence, Italy.
Departments of Physiology and Surgery, UCSF, San Francisco, California, USA.
Department of Human Pathology and Oncology, University of Florence, Florence, Italy.
CEA, Institut de Biologie et Technologies de Saclay (iBiTec-S), Service de pharmacologie et d'immuno analyse (SPI), Gif sur Yvette, France.
Pharmacology Department, Chiesi Pharmaceuticals, Parma, Italy.
Department of Pharmaceutical Chemistry, University of Ferrara, Ferrara, Italy
| | - Daniela Massi
- Center of Excellence for the Study of Inflammation, University of Ferrara, Ferrara, Italy.
Clinical Pharmacology Unit, Department of Critical Care Medicine and Surgery, University of Florence, Florence, Italy.
Departments of Physiology and Surgery, UCSF, San Francisco, California, USA.
Department of Human Pathology and Oncology, University of Florence, Florence, Italy.
CEA, Institut de Biologie et Technologies de Saclay (iBiTec-S), Service de pharmacologie et d'immuno analyse (SPI), Gif sur Yvette, France.
Pharmacology Department, Chiesi Pharmaceuticals, Parma, Italy.
Department of Pharmaceutical Chemistry, University of Ferrara, Ferrara, Italy
| | - Christophe Creminon
- Center of Excellence for the Study of Inflammation, University of Ferrara, Ferrara, Italy.
Clinical Pharmacology Unit, Department of Critical Care Medicine and Surgery, University of Florence, Florence, Italy.
Departments of Physiology and Surgery, UCSF, San Francisco, California, USA.
Department of Human Pathology and Oncology, University of Florence, Florence, Italy.
CEA, Institut de Biologie et Technologies de Saclay (iBiTec-S), Service de pharmacologie et d'immuno analyse (SPI), Gif sur Yvette, France.
Pharmacology Department, Chiesi Pharmaceuticals, Parma, Italy.
Department of Pharmaceutical Chemistry, University of Ferrara, Ferrara, Italy
| | - Natalya Vaksman
- Center of Excellence for the Study of Inflammation, University of Ferrara, Ferrara, Italy.
Clinical Pharmacology Unit, Department of Critical Care Medicine and Surgery, University of Florence, Florence, Italy.
Departments of Physiology and Surgery, UCSF, San Francisco, California, USA.
Department of Human Pathology and Oncology, University of Florence, Florence, Italy.
CEA, Institut de Biologie et Technologies de Saclay (iBiTec-S), Service de pharmacologie et d'immuno analyse (SPI), Gif sur Yvette, France.
Pharmacology Department, Chiesi Pharmaceuticals, Parma, Italy.
Department of Pharmaceutical Chemistry, University of Ferrara, Ferrara, Italy
| | - Romina Nassini
- Center of Excellence for the Study of Inflammation, University of Ferrara, Ferrara, Italy.
Clinical Pharmacology Unit, Department of Critical Care Medicine and Surgery, University of Florence, Florence, Italy.
Departments of Physiology and Surgery, UCSF, San Francisco, California, USA.
Department of Human Pathology and Oncology, University of Florence, Florence, Italy.
CEA, Institut de Biologie et Technologies de Saclay (iBiTec-S), Service de pharmacologie et d'immuno analyse (SPI), Gif sur Yvette, France.
Pharmacology Department, Chiesi Pharmaceuticals, Parma, Italy.
Department of Pharmaceutical Chemistry, University of Ferrara, Ferrara, Italy
| | - Maurizio Civelli
- Center of Excellence for the Study of Inflammation, University of Ferrara, Ferrara, Italy.
Clinical Pharmacology Unit, Department of Critical Care Medicine and Surgery, University of Florence, Florence, Italy.
Departments of Physiology and Surgery, UCSF, San Francisco, California, USA.
Department of Human Pathology and Oncology, University of Florence, Florence, Italy.
CEA, Institut de Biologie et Technologies de Saclay (iBiTec-S), Service de pharmacologie et d'immuno analyse (SPI), Gif sur Yvette, France.
Pharmacology Department, Chiesi Pharmaceuticals, Parma, Italy.
Department of Pharmaceutical Chemistry, University of Ferrara, Ferrara, Italy
| | - Pier Giovanni Baraldi
- Center of Excellence for the Study of Inflammation, University of Ferrara, Ferrara, Italy.
Clinical Pharmacology Unit, Department of Critical Care Medicine and Surgery, University of Florence, Florence, Italy.
Departments of Physiology and Surgery, UCSF, San Francisco, California, USA.
Department of Human Pathology and Oncology, University of Florence, Florence, Italy.
CEA, Institut de Biologie et Technologies de Saclay (iBiTec-S), Service de pharmacologie et d'immuno analyse (SPI), Gif sur Yvette, France.
Pharmacology Department, Chiesi Pharmaceuticals, Parma, Italy.
Department of Pharmaceutical Chemistry, University of Ferrara, Ferrara, Italy
| | - Daniel P. Poole
- Center of Excellence for the Study of Inflammation, University of Ferrara, Ferrara, Italy.
Clinical Pharmacology Unit, Department of Critical Care Medicine and Surgery, University of Florence, Florence, Italy.
Departments of Physiology and Surgery, UCSF, San Francisco, California, USA.
Department of Human Pathology and Oncology, University of Florence, Florence, Italy.
CEA, Institut de Biologie et Technologies de Saclay (iBiTec-S), Service de pharmacologie et d'immuno analyse (SPI), Gif sur Yvette, France.
Pharmacology Department, Chiesi Pharmaceuticals, Parma, Italy.
Department of Pharmaceutical Chemistry, University of Ferrara, Ferrara, Italy
| | - Nigel W. Bunnett
- Center of Excellence for the Study of Inflammation, University of Ferrara, Ferrara, Italy.
Clinical Pharmacology Unit, Department of Critical Care Medicine and Surgery, University of Florence, Florence, Italy.
Departments of Physiology and Surgery, UCSF, San Francisco, California, USA.
Department of Human Pathology and Oncology, University of Florence, Florence, Italy.
CEA, Institut de Biologie et Technologies de Saclay (iBiTec-S), Service de pharmacologie et d'immuno analyse (SPI), Gif sur Yvette, France.
Pharmacology Department, Chiesi Pharmaceuticals, Parma, Italy.
Department of Pharmaceutical Chemistry, University of Ferrara, Ferrara, Italy
| | - Pierangelo Geppetti
- Center of Excellence for the Study of Inflammation, University of Ferrara, Ferrara, Italy.
Clinical Pharmacology Unit, Department of Critical Care Medicine and Surgery, University of Florence, Florence, Italy.
Departments of Physiology and Surgery, UCSF, San Francisco, California, USA.
Department of Human Pathology and Oncology, University of Florence, Florence, Italy.
CEA, Institut de Biologie et Technologies de Saclay (iBiTec-S), Service de pharmacologie et d'immuno analyse (SPI), Gif sur Yvette, France.
Pharmacology Department, Chiesi Pharmaceuticals, Parma, Italy.
Department of Pharmaceutical Chemistry, University of Ferrara, Ferrara, Italy
| | - Riccardo Patacchini
- Center of Excellence for the Study of Inflammation, University of Ferrara, Ferrara, Italy.
Clinical Pharmacology Unit, Department of Critical Care Medicine and Surgery, University of Florence, Florence, Italy.
Departments of Physiology and Surgery, UCSF, San Francisco, California, USA.
Department of Human Pathology and Oncology, University of Florence, Florence, Italy.
CEA, Institut de Biologie et Technologies de Saclay (iBiTec-S), Service de pharmacologie et d'immuno analyse (SPI), Gif sur Yvette, France.
Pharmacology Department, Chiesi Pharmaceuticals, Parma, Italy.
Department of Pharmaceutical Chemistry, University of Ferrara, Ferrara, Italy
| |
Collapse
|
15
|
Swarna VM, Undem BJ, Korlipara VL. Design and synthesis of 3,5-disubstituted benzamide analogues of DNK333 as dual NK1/NK2 receptor probes. Bioorg Med Chem Lett 2006; 17:890-4. [PMID: 17169559 DOI: 10.1016/j.bmcl.2006.11.064] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/16/2006] [Revised: 11/16/2006] [Accepted: 11/20/2006] [Indexed: 10/23/2022]
Abstract
N-[(R,R)-(E)-(3,4-dichlorobenzyl)-3-(2-oxoazepan-3-yl)carbamoyl]allyl-N-methyl-3,5-bis(trifluoromethyl)benzamide (DNK333, 1b) has been reported to be a potent and balanced dual neurokinin (tachykinin) receptor antagonist. A recent clinical trial using DNK333 has shown that it blocks the NKA-induced bronchoconstriction in patients with asthma. A series of six analogues 3-8 derived from modification of 3,5-bis(trifluoromethyl)benzamide moiety of DNK333 has been synthesized to serve as the dual NK(1)/NK(2) receptor probes. The 3,5-dinitro substituted benzamide compound 3 was found to possess potent and balanced dual NK(1)/NK(2) receptor antagonist activities (pK(b)=8.4 for the NK(1) receptors, pK(b)=7.87 for the NK(2) receptors) in the functional assay using guinea pig trachea. Furthermore, SAR analysis suggests that steric, electronic, and lipophilic characteristics of substituents in the benzamide region of DNK333 have a crucial effect on both the NK(1) and NK(2) receptor antagonist activities.
Collapse
Affiliation(s)
- Venkat Manoj Swarna
- Department of Pharmaceutical Sciences, St. John's University, 8000 Utopia Parkway, Queens, NY 11439, USA
| | | | | |
Collapse
|
16
|
Yoshihara S, Morimoto H, Ohori M, Yamada Y, Abe T, Arisaka O. A neuroactive steroid inhibits guinea pig airway sensory nerves via Maxi-K channel activation. Int Arch Allergy Immunol 2006; 141:31-6. [PMID: 16804322 DOI: 10.1159/000094179] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/01/2005] [Accepted: 03/06/2006] [Indexed: 11/19/2022] Open
Abstract
BACKGROUND Although neurogenic inflammation via the activation of C-fibers in the airway may have an important role in the pathogenesis of asthma, their regulatory mechanism remains uncertain. OBJECTIVE The pharmacological profiles of a neuroactive steroid, allotetrahydrocorticosterone, on the activation of C-fibers in airway tissues were investigated, and the mechanism how a neuroactive steroid regulates airway inflammatory reactions was clarified. METHODS The effects of allotetrahydrocorticosterone on electrical field stimulation-induced bronchial smooth muscle contraction in guinea pig airway tissues were investigated. The influences of K+ channel blockers and intracellular protein inhibitors on the effects of allotetrahydrocorticosterone were examined. RESULTS Allotetrahydrocorticosterone dose-dependently inhibited electrical field stimulation-induced guinea pig bronchial smooth muscle contraction. The inhibitory effects of allotetrahydrocorticosterone on electrical field stimulation-induced bronchial contraction were reduced by the pretreatment of Maxi-K+ channel blockers, iberiotoxin and charybdotoxin, but not other K+ channel blockers, dendrotoxin or glibenclamide. Pretreatment with pertussis toxin diminished the inhibitory effect of allotetrahydrocorticosterone, but not an adenylate cyclase inhibitor, SQ 22536, nor a specific inhibitor of mitogen-activated protein kinase kinase, PD 98059. CONCLUSIONS These findings suggest that allotetrahydrocorticosterone negatively modulates the activation of C-fibers in guinea pig airway tissues via the opening of Maxi-K+ channels and a pertussis toxin-sensitive G-protein-coupled mechanism.
Collapse
Affiliation(s)
- Shigemi Yoshihara
- Department of Pediatrics, Dokkyo University School of Medicine, Tochigi, Japan.
| | | | | | | | | | | |
Collapse
|
17
|
Molfino NA, Jeffery PK. Chronic obstructive pulmonary disease: histopathology, inflammation and potential therapies. Pulm Pharmacol Ther 2006; 20:462-72. [PMID: 16798034 DOI: 10.1016/j.pupt.2006.04.003] [Citation(s) in RCA: 23] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 07/20/2005] [Revised: 02/07/2006] [Accepted: 04/18/2006] [Indexed: 12/21/2022]
Abstract
Chronic obstructive pulmonary disease (COPD) is a major worldwide health burden with increasing morbidity, mortality and health care cost. It is a slowly progressive chronic inflammatory condition that affects the conducting airways (both large and small) and lung parenchyma. In COPD, inflammation is evident early on even in mild disease and increases with disease severity. Recent advances in our knowledge demonstrate, by comparison with asthma, the distinctive, "abnormal" or exaggerated inflammatory processes involved in the pathogenesis of COPD and thus identify novel therapeutic targets that could potentially impact on disease progression. The present review will focus on what is known of the abnormal inflammatory response of COPD in different regions of the conducting airways and lung. Novel, potentially promising approaches to therapy are presented.
Collapse
|
18
|
Schechter LE, Ring RH, Beyer CE, Hughes ZA, Khawaja X, Malberg JE, Rosenzweig-Lipson S. Innovative approaches for the development of antidepressant drugs: current and future strategies. NeuroRx 2006; 2:590-611. [PMID: 16489368 PMCID: PMC1201318 DOI: 10.1602/neurorx.2.4.590] [Citation(s) in RCA: 155] [Impact Index Per Article: 8.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/16/2022]
Abstract
Depression is a highly debilitating disorder that has been estimated to affect up to 21% of the world population. Despite the advances in the treatment of depression with selective serotonin reuptake inhibitors (SSRIs) and serotonin and norepinephrine reuptake inhibitors (SNRIs), there continue to be many unmet clinical needs with respect to both efficacy and side effects. These needs range from efficacy in treatment resistant patients, to improved onset, to reductions in side effects such as emesis or sexual dysfunction. To address these needs, there are numerous combination therapies and novel targets that have been identified that may demonstrate improvements in one or more areas. There is tremendous diversity in the types of targets and approaches being taken. At one end of a spectrum is combination therapies that maintain the benefits associated with SSRIs but attempt to either improve efficacy or reduce side effects by adding additional mechanisms (5-HT1A, 5-HT1B, 5-HT1D, 5-HT2C, alpha-2A). At the other end of the spectrum are more novel targets, such as neurotrophins (BDNF, IGF), based on recent findings that antidepressants induce neurogenesis. In between, there are many approaches that range from directly targeting serotonin receptors (5-HT2C, 5-HT6) to targeting the multiplicity of potential mechanisms associated with excitatory (glutamate, NMDA, mGluR2, mGluR5) or inhibitory amino acid systems (GABA) or peptidergic systems (neurokinin 1, corticotropin-releasing factor 1, melanin-concentrating hormone 1, V1b). The present review addresses the most exciting approaches and reviews the localization, neurochemical and behavioral data that provide the supporting rationale for each of these targets or target combinations.
Collapse
Affiliation(s)
- Lee E Schechter
- Discovery Neuroscience, Wyeth Research, CN 8000, Princeton, New Jersey 08543, USA.
| | | | | | | | | | | | | |
Collapse
|
19
|
Tachykinin. Br J Pharmacol 2006. [DOI: 10.1038/sj.bjp.0706546] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022] Open
|
20
|
De Swert KO, Joos GF. Extending the understanding of sensory neuropeptides. Eur J Pharmacol 2006; 533:171-81. [PMID: 16464447 DOI: 10.1016/j.ejphar.2005.12.066] [Citation(s) in RCA: 82] [Impact Index Per Article: 4.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/11/2005] [Accepted: 12/13/2005] [Indexed: 11/22/2022]
Abstract
The tachykinins substance P and neurokinin A are present in human airways, in sensory nerves and immune cells. Tachykinins can be recovered from the airways after inhalation of ozone, cigarette smoke or allergen. They interact in the airways with tachykinin NK1, NK2 and NK3 receptors to cause bronchoconstriction, plasma protein extravasation, and mucus secretion and to attract and activate immune cells. In preclinical studies they have been implicated in the pathophysiology of asthma and chronic obstructive pulmonary disease, including allergen- and cigarette smoke induced airway inflammation and bronchial hyperresponsiveness and mucus secretion. Dual NK1/NK2 or triple NK1/NK2/NK3 tachykinin receptor antagonists offer therapeutic potential in airway diseases such as asthma and chronic obstructive pulmonary disease.
Collapse
Affiliation(s)
- Katelijne O De Swert
- Department of Respiratory Diseases, Faculty of Medicine and Health Sciences, Ghent University, Belgium
| | | |
Collapse
|
21
|
Geppetti P, Materazzi S, Nicoletti P. The transient receptor potential vanilloid 1: role in airway inflammation and disease. Eur J Pharmacol 2006; 533:207-14. [PMID: 16464449 DOI: 10.1016/j.ejphar.2005.12.063] [Citation(s) in RCA: 142] [Impact Index Per Article: 7.9] [Reference Citation Analysis] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 12/13/2005] [Indexed: 12/25/2022]
Abstract
The transient receptor potential vanilloid 1 (TRPV1) is an excitatory cation channel, rather selectively expressed in a subpopulation of nociceptive, primary sensory neurons that promote neurogenic inflammation via neuropeptide release. TRPV1 is activated by noxious temperature, low extracellular pH and diverse lipid derivatives, and is uniquely sensitive to vanilloid molecules, including capsaicin. TRPV1 expression and sensitivity is highly regulated by diverse G protein-coupled and tyrosine kinase receptors. Other exogenous or endogenous chemical agents, including reactive oxygen species, ethanol and hydrogen sulphide sensitize/activate TRPV1. In the airways, TRPV1 agonists cause cough, bronchoconstriction, microvascular leakage, hyperreactivity and hypersecretion. Patients with asthma and chronic obstructive pulmonary disease are more sensitive to the tussive effect of TRPV1 agonists and TRPV1 activation may contribute to respiratory symptoms caused by acidic media present in the airways during asthma exacerbation, gastroesophageal reflux induced asthma or in other conditions. TRPV1 antagonists may be useful in the treatment of these diseases.
Collapse
Affiliation(s)
- Pierangelo Geppetti
- Clinical Pharmacology Unit, Department of Critical Care Medicine and Surgery, University of Florence, Italy.
| | | | | |
Collapse
|
22
|
Pelaia G, Vatrella A, Gallelli L, Renda T, Caputi M, Maselli R, Marsico SA. Biological targets for therapeutic interventions in COPD: clinical potential. Int J Chron Obstruct Pulmon Dis 2006; 1:321-34. [PMID: 18046869 PMCID: PMC2707155 DOI: 10.2147/copd.2006.1.3.321] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/09/2023] Open
Abstract
COPD is a widespread inflammatory respiratory disorder characterized by a progressive, poorly reversible airflow limitation. Currently available therapies are mostly based on those used to treat asthma. However, such compounds are not able to effectively reduce the gradual functional deterioration, as well as the ongoing airway and lung inflammation occurring in COPD patients. Therefore, there is an urgent need to improve the efficacy of the existing drug classes and to develop new treatments, targeting the main cellular and molecular mechanisms underlying disease pathogenesis. These therapeutic strategies will be highlighted in the present review.
Collapse
Affiliation(s)
- Girolamo Pelaia
- Department of Experimental and Clinical Medicine, University "Magna Graecia" of Catanzaro, Italy.
| | | | | | | | | | | | | |
Collapse
|
23
|
Yoshihara S, Morimoto H, Ohori M, Yamada Y, Abe T, Arisaka O. A neuroactive steroid, allotetrahydrocorticosterone inhibits sensory nerves activation in guinea-pig airways. Neurosci Res 2005; 53:210-5. [PMID: 16055215 DOI: 10.1016/j.neures.2005.06.017] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/23/2005] [Revised: 06/22/2005] [Accepted: 06/24/2005] [Indexed: 11/26/2022]
Abstract
We examined the effects of a neuroactive steroid, allotetrahydrocorticosterone on the activation of capsaicin-sensitive afferent sensory nerves (C-fibers). Allotetrahydrocorticosterone (0.0001-1.0 microg/ml) dose-dependently inhibited electrical field stimulation-induced guinea-pig bronchial smooth muscle contraction, but not the substance P-induced contraction at 1.0 microg/ml. Allotetrahydrocorticosterone (0.01-1.0 microg/ml) also reduced the capsaicin-induced release of substance P-like immunoreactivity from guinea-pig airway tissues in a dose-dependent manner. The inhibitory effect of allotetrahydrocorticosterone on electrical field stimulation-induced bronchial contraction were reduced by the pretreatment of voltage-dependent K+ channel blockers, tetraethylammonium (1 mM). This evidence suggests that allotetrahydrocorticosterone negatively modulate the activation of C-fibers and substance P release from their endings in airway tissues via the opening of voltage-dependent K+ channels.
Collapse
Affiliation(s)
- Shigemi Yoshihara
- Department of Pediatrics, Dokkyo University School of Medicine, 880 Kitakobayashi, Mibu-machi, Shimotsuga-gun, Tochigi 321-0293, Japan
| | | | | | | | | | | |
Collapse
|
24
|
Yoshihara S, Morimoto H, Ohori M, Yamada Y, Abe T, Arisaka O. Endogenous cannabinoid receptor agonists inhibit neurogenic inflammations in guinea pig airways. Int Arch Allergy Immunol 2005; 138:80-7. [PMID: 16103691 DOI: 10.1159/000087361] [Citation(s) in RCA: 16] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/15/2005] [Accepted: 05/19/2005] [Indexed: 11/19/2022] Open
Abstract
BACKGROUND Although neurogenic inflammation via the activation of C fibers in the airway must have an important role in the pathogenesis of asthma, their regulatory mechanism remains uncertain. OBJECTIVE The pharmacological profiles of endogenous cannabinoid receptor agonists on the activation of C fibers in airway tissues were investigated and the mechanisms how cannabinoids regulate airway inflammatory reactions were clarified. METHODS The effects of endogenous cannabinoid receptor agonists on electrical field stimulation-induced bronchial smooth muscle contraction, capsaicin-induced bronchoconstriction and capsaicin-induced substance P release in guinea pig airway tissues were investigated. The influences of cannabinoid receptor antagonists and K+ channel blockers to the effects of cannabinoid receptor agonists on these respiratory reactions were examined. RESULTS Both endogenous cannabinoid receptor agonists, anandamide and palmitoylethanolamide, inhibited electrical field stimulation-induced guinea pig bronchial smooth muscle contraction, but not neurokinin A-induced contraction. A cannabinoid CB2 antagonist, SR 144528, reduced the inhibitory effect of endogenous agonists, but not a cannabinoid CB1 antagonist, SR 141716A. Inhibitory effects of agonists were also reduced by the pretreatment of large conductance Ca2+ -activated K+ channel (maxi-K+ channel) blockers, iberiotoxin and charybdotoxin, but not by other K+ channel blockers, dendrotoxin or glibenclamide. Anandamide and palmitoylethanolamide blocked the capsaicin-induced release of substance P-like immunoreactivity from guinea pig airway tissues. Additionally, intravenous injection of palmitoylethanolamide dose-dependently inhibited capsaicin-induced guinea pig bronchoconstriction, but not neurokinin A-induced reaction. However, anandamide did not reduce capsaicin-induced guinea pig bronchoconstriction. CONCLUSIONS These findings suggest that endogenous cannabinoid receptor agonists inhibit the activation of C fibers via cannabinoid CB2 receptors and maxi-K+ channels in guinea pig airways.
Collapse
Affiliation(s)
- Shigemi Yoshihara
- Department of Pediatrics, Dokkyo University School of Medicine, 880 Kitakobayashi, Mibu-machi, Shimotsuga-gun, Tochigi 321-0293, Japan.
| | | | | | | | | | | |
Collapse
|
25
|
Abstract
Chronic obstructive pulmonary disease (COPD) is a major and increasing global health problem that is now a leading cause of death. COPD is associated with a chronic inflammatory response, predominantly in small airways and lung parenchyma, which is characterized by increased numbers of macrophages, neutrophils, and T lymphocytes. The inflammatory mediators involved in COPD have not been clearly defined, in contrast to asthma, but it is now apparent that many lipid mediators, inflammatory peptides, reactive oxygen and nitrogen species, chemokines, cytokines, and growth factors are involved in orchestrating the complex inflammatory process that results in small airway fibrosis and alveolar destruction. Many proteases are also involved in the inflammatory process and are responsible for the destruction of elastin fibers in the lung parenchyma, which is the hallmark of emphysema. The identification of inflammatory mediators and understanding their interactions is important for the development of anti-inflammatory treatments for this important disease.
Collapse
Affiliation(s)
- Peter J Barnes
- National Heart and Lung Institute, Imperial College School of Medicine, Dovehouse St, London SW3 6LY, United Kingdom.
| |
Collapse
|
26
|
Meini S, Catalani C, Bellucci F, Cucchi P, Giuliani S, Zappitelli S, Rotondaro L, Pasqui F, Guidi A, Altamura M, Giolitti A, Maggi CA. Pharmacology of an original and selective nonpeptide antagonist ligand for the human tachykinin NK2 receptor. Eur J Pharmacol 2005; 516:104-11. [PMID: 15925360 DOI: 10.1016/j.ejphar.2005.04.033] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/03/2005] [Revised: 04/18/2005] [Accepted: 04/22/2005] [Indexed: 10/25/2022]
Abstract
The pharmacological outline of a novel and original antagonist at the human tachykinin NK2 receptor is presented, namely MEN13510 (N-N'-bis-[2-(1H-indol-3-yl)-ethyl]-N,N'-bis-(3-thiomorpholin-4-yl-propyl)-phthalamide). MEN13510 retained nanomolar affinity for the human tachykinin NK2 receptor (Ki 6.4 nM), and micromolar affinity for the human tachykinin NK1 and NK3 receptors. A competitive antagonism is indicated by the Schild analysis (pK(B) 7.8, slope -0.94) of concentration-response curves of NKA induced inositolphosphates accumulation in Chinese hamster ovary (CHO) cells expressing the human NK2 receptor in the presence of MEN13510 (30-300 nM concentration range). The MEN13510 interaction with the human NK2 receptor was evaluated by means of heterologous inhibition binding experiments, by using agonist and antagonist radioligands ([125I]NKA, [3H]nepadutant, [3H]saredutant) at a series of mutant receptors having single aminoacidic substitutions of residues located in transmembrane (TM) segments 3, 4, 5, 6, and 7. MEN13510 affinity was not affected by the mutations in TM 3 and 4 (Q109A, F112A, T171A, C167G), and it was reduced by 10-fold at the I202F mutant, but not at the Y206A (TM4). Amongst the investigated mutants bearing the mutated residues in TM6 (F270A, Y266F, W263A) only F270A decreased the MEN13510 affinity by 7-fold. Even mutations in TM7 did reduce MEN13510 affinity by 32-fold (Y289T, but not Y289F) and 13-fold (F293A). Studied mutations represent the human tachykinin NK2 receptor discriminants involved in the binding of previously reported peptidic and nonpeptidic antagonists, against which results obtained with MEN13510 are compared. Results indicate that the binding site of this antagonist is, at least in part, overlapping to that described for NKA or saredutant. Finally we show that MEN13510 retains nanomolar affinity for the recently discovered splice variant of the human tachykinin NK2 receptor, namely beta isoform, as it has been described for the nonpeptide antagonist saredutant.
Collapse
Affiliation(s)
- Stefania Meini
- Department of Pharmacology, Menarini Ricerche S.p.A., via Rismondo 12A, Florence, Italy.
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
27
|
Molfino NA. Drugs in clinical development for chronic obstructive pulmonary disease. Respiration 2005; 72:105-12. [PMID: 15753645 DOI: 10.1159/000083411] [Citation(s) in RCA: 18] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/09/2004] [Accepted: 06/29/2004] [Indexed: 02/04/2023] Open
Abstract
Many drugs may be potentially useful in the treatment of chronic obstructive pulmonary disease (COPD), but relatively few become available for human use due to lack of safety, lack of efficacy, or both. This is an inherent risk in the drug development process, which coupled with the limited understanding of the molecular pathogenesis of COPD, has produced a trend toward improving existing compounds rather than to develop new compounds. This review focuses on improved existing compounds and newly discovered compounds that are in clinical trials, but not yet marketed. The improved existing compounds include: isomers of the long-acting bronchodilators, once-daily beta2-adrenoceptor agonists, anticholinergics and corticosteroids. The pool of novel compounds is in constant fluctuation and comprises anti-inflammatory drugs, antioxidants, leukotriene modifiers and a number of compounds aimed at treating different aspects of COPD such as pulmonary hypertension and hypophosphatemia.
Collapse
|
28
|
Yoshihara S, Morimoto H, Ohori M, Yamada Y, Abe T, Arisaka O. The cannabinoid receptor agonist WIN 55212-2 inhibits neurogenic inflammations in airway tissues. J Pharmacol Sci 2005; 98:77-82. [PMID: 15888960 DOI: 10.1254/jphs.fp0050171] [Citation(s) in RCA: 13] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022] Open
Abstract
We examined the effects of a cannabinoid receptor agonist, (R)-(+)-[2,3-dihydro-5-methyl-3-[(4-merpholino)methyl]pyrrolo-[1,2,3-de]-1,4-benzoxazin-6-yl](1-naphthyl)methanone (WIN 55212-2), on various respiratory reactions induced by the activation of capsaicin-sensitive afferent sensory nerves (C-fibers). WIN 55212-2 significantly inhibited capsaicin-induced guinea pig bronchoconstriction, but not the neurokinin A-induced reaction. Intravenous injection of WIN 55212-2 also blocked cigarette smoke-induced rat tracheal plasma extravasation. However, substance P-induced rat tracheal plasma extravasation was not affected by the administration of WIN 55212-2. A cannabinoid CB(2) receptor antagonist, {N-[(1S)-endo-1,3,3-trimethylbicyclo[2.2.1] heptan-2-yl]-5-(4-chloro-3-methylphenyl)-1-(4-methylbenzyl)pyrazole-3-carboxamide} (SR 144528) reduced the inhibitory effects of WIN 55212-2, but not a cannabinoid CB(1) antagonist, [N-(piperidin-1-yl)-5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-1H-pyrazole-3-carboxamidehydrochloride] (SR 141716A). A Maxi-K(+) channel opener, 1-(2'-hydroxy-5'-trifluoromethylphenyl)-5-trifluoromethyl-2(3H)benzimidazolone (NS 1619), specifically inhibited capsaicin-induced guinea pig bronchoconstriction and cigarette smoke-induced rat tracheal plasma extravasation. These findings suggest that WIN 55212-2 inhibits the activation of C-fibers via cannabinoid CB(2) receptors and Maxi-K(+) channels and reduces airway neurogenic inflammatory reactions in vivo.
Collapse
Affiliation(s)
- Shigemi Yoshihara
- Department of Pediatrics, Dokkyo University School of Medicine, Tochigi 321-0293, Japan.
| | | | | | | | | | | |
Collapse
|
29
|
Gerspacher M. Selective and combined neurokinin receptor antagonists. PROGRESS IN MEDICINAL CHEMISTRY 2005; 43:49-103. [PMID: 15850823 DOI: 10.1016/s0079-6468(05)43003-9] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/02/2023]
Affiliation(s)
- Marc Gerspacher
- Novartis Institutes for Biomedical Research Basel, Novartis Pharma AG, Switzerland.
| |
Collapse
|
30
|
Yoshihara S, Morimoto H, Yamada Y, Abe T, Arisaka O. Cannabinoid receptor agonists inhibit sensory nerve activation in guinea pig airways. Am J Respir Crit Care Med 2004; 170:941-6. [PMID: 15306537 DOI: 10.1164/rccm.200306-775oc] [Citation(s) in RCA: 20] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022] Open
Abstract
We examined the effects of cannabinoid receptor agonists on various respiratory reactions induced by the activation of capsaicin-sensitive afferent sensory nerves (C-fibers). (R)-(+)-[2,3-dihydro-5-methyl-3-[(4-merpholino)methyl]pyrrolo-[1,2,3-de]-1,4-benzoxazin-6-yl](1-naphthyl)methanone (WIN 55212-2) dose-dependently inhibited electrical field stimulation- and capsaicin-induced guinea pig bronchial smooth muscle contraction, but not the neurokinin A-induced contraction. A cannabinoid CB2 receptor antagonist, [N-[(1S)-endo-1,3,3-trimethylbicyclo[2.2.1]heptan-2-yl]-5-(4-chloro-3-methylphenyl)-1-(4-methylbenzyl)pyrazole-3-carboxamide] (SR 144528), reduced the inhibitory effect of WIN 55212-2, but not a cannabinoid CB1 antagonist, [N-(piperidin-1-yl)-5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-1H-pyrazole-3-carboxamidehydrochloride] (SR 141716A). A cannabinoid CB2 agonist, JWH 133, also inhibited electrical field stimulation-induced guinea pig bronchial smooth muscle contraction and its inhibitory effect was blocked by SR 144528. The inhibitory effect of WIN 55212-2 on electrical field stimulation-induced bronchial contraction was reduced by the pretreatment of large conductance Ca(2+)-activated K+ channel (Maxi-K+ channel) blockers, iberiotoxin and charybdotoxin, but not other K+ channel blockers, dendrotoxin or glibenclamide. A Maxi-K+ channel opener, 1-(2'-hydroxy-5'-trifluoromethylphenyl)-5-trifluoromethyl-2(3H)benzimidazolone (NS1619), inhibited bronchial contraction induced by electrical field stimulation. WIN 55212-2 and JWH 133 blocked the capsaicin-induced release of substance P-like immunoreactivity from guinea pig airway tissues. These findings suggest that WIN 55212-2 inhibit the activation of C-fibers via cannabinoid CB2 receptors and Maxi-K+ channels in guinea pig airways.
Collapse
Affiliation(s)
- Shigemi Yoshihara
- Department of Pediatric, Dokkyo University School of Medicine, Tochigi, Japan.
| | | | | | | | | |
Collapse
|
31
|
Abstract
Chronic obstructive pulmonary disease (COPD) is a common, smoking-related, severe respiratory condition characterised by progressive, irreversible airflow limitation. Current treatment of COPD is symptomatic, with no drugs capable of halting the relentless progression of airflow obstruction. Better understanding of the airway inflammation, oxidative stress and alveolar destruction that characterise COPD has delineated new disease targets, with consequent identification of novel compounds with therapeutic potential. These new drugs include aids to smoking cessation (e.g. bupropion) and improvements to existing therapies, for example long-acting rather than short-acting bronchodilators, as well as combination therapy. New antiproteases include acyl-enzyme and transition state inhibitors of neutrophil elastase (e.g. sivelestat and ONO-6818), matrix metalloprotease inhibitors (e.g. batimastat), cathepsin inhibitors and peptide protease inhibitors (e.g. DX-890 [EPI-HNE-4] and trappin-2). New antioxidants include superoxide dismutase mimetics (e.g. AEOL-10113) and spin trap compounds (e.g. N-tert-butyl-alpha-phenylnitrone). New anti-inflammatory interventions include phosphodiesterase-4 inhibitors (e.g. cilomilast), inhibitors of tumour necrosis factor-alpha (e.g. humanised monoclonal antibodies), adenosine A(2a) receptor agonists (e.g. CGS-21680), adhesion molecule inhibitors (e.g. bimosiamose [TBC1269]), inhibitors of nuclear factor-kappaB (e.g. the naturally occurring compounds hypoestoxide and (-)-epigallocatechin-3-gallate) and activators of histone deacetylase (e.g. theophylline). There are also selective inhibitors of specific extracellular mediators such as chemokines (e.g. CXCR2 and CCR2 antagonists) and leukotriene B(4) (e.g. SB201146), and of intracellular signal transduction molecules such as p38 mitogen activated protein kinase (e.g. RWJ67657) and phosphoinositide 3-kinase. Retinoids may be one of the few potential treatments capable of reversing alveolar destruction in COPD, and a number of compounds are in clinical trial (e.g. all-trans-retinoic acid). Talniflumate (MSI-1995), an inhibitor of human calcium-activated chloride channels, has been developed to treat mucous hypersecretion. In addition, the purinoceptor P2Y(2) receptor agonist diquafosol (INS365) is undergoing clinical trials to increase mucus clearance. The challenge to transferral of these new compounds from preclinical research to disease management is the design of effective clinical trials. The current scarcity of well characterised surrogate markers predicts that long-term studies in large numbers of patients will be needed to monitor changes in disease progression.
Collapse
Affiliation(s)
- Louise E Donnelly
- Thoracic Medicine, National Heart & Lung Institute, Imperial College, London, UK
| | | |
Collapse
|
32
|
Affiliation(s)
- A Brack
- Klinik für Anaesthesiologie und operative Intensivmedizin, Universitätsklinikum Benjamin Franklin, Freie Universität Berlin, Hindenburgdamm 30, D-12200, Berlin, Germany.
| | | |
Collapse
|
33
|
Synthesis and conformational analysis of Substance P antagonist analogues based on a 1,7-naphthyridine scaffold. Tetrahedron 2003. [DOI: 10.1016/s0040-4020(03)00732-4] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/21/2022]
|
34
|
Elsawa SF, Taylor W, Petty CC, Marriott I, Weinstock JV, Bost KL. Reduced CTL response and increased viral burden in substance P receptor-deficient mice infected with murine gamma-herpesvirus 68. JOURNAL OF IMMUNOLOGY (BALTIMORE, MD. : 1950) 2003; 170:2605-12. [PMID: 12594288 DOI: 10.4049/jimmunol.170.5.2605] [Citation(s) in RCA: 22] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/19/2022]
Abstract
One component of the protective host response against mucosal pathogens includes the local production and increased expression of certain neuropeptides and their receptors. The present study further demonstrates this fact by investigating the contribution that substance P receptor expression makes toward immunity against a gamma-herpesvirus infection. Following intragastric inoculation with murine gamma-herpesvirus 68 (gamma HV-68), expression of substance P and its receptor was increased in mucosal and peripheral lymphoid organs in wild-type strains of mice. These results suggested that this receptor/ligand pair might be an important component of the host response against this viral infection. Such a hypothesis was supported by the demonstration that mice, genetically deficient in substance P receptor expression, showed an increased viral burden when compared with syngeneic C57BL/6 mice. Furthermore, substance P receptor-deficient mice showed a reduced CTL response against gamma HV-68, suggesting a mechanism to explain this increased viral burden. Such limitations in the Ag-specific CTL response in substance P receptor-deficient mice could result from lowered expression of IL-12 during viral infection. Consistent with this hypothesis, increases in mRNA encoding IL-12 and secretion of this cytokine into sera of infected, wild-type animals were markedly reduced in substance P receptor-deficient mice. These studies demonstrate that genetic elimination of substance P receptors in mice results in an increased gamma-herpesvirus burden and an altered host response.
Collapse
MESH Headings
- Animals
- Down-Regulation/genetics
- Down-Regulation/immunology
- Epitopes, T-Lymphocyte/immunology
- Gene Expression Regulation/immunology
- Herpesviridae Infections/genetics
- Herpesviridae Infections/immunology
- Herpesviridae Infections/virology
- Interleukin-12/antagonists & inhibitors
- Interleukin-12/biosynthesis
- Lac Operon/immunology
- Leukocytosis/genetics
- Leukocytosis/immunology
- Leukocytosis/virology
- Mice
- Mice, Inbred C57BL
- Mice, Knockout
- Protein Precursors/biosynthesis
- Protein Precursors/genetics
- RNA, Messenger/genetics
- Receptors, Neurokinin-1/deficiency
- Receptors, Neurokinin-1/genetics
- Receptors, Neurokinin-1/physiology
- Rhadinovirus/immunology
- Rhadinovirus/physiology
- T-Lymphocytes, Cytotoxic/immunology
- T-Lymphocytes, Cytotoxic/metabolism
- T-Lymphocytes, Cytotoxic/virology
- Tachykinins/biosynthesis
- Tachykinins/genetics
- Virus Latency/genetics
- Virus Latency/immunology
Collapse
Affiliation(s)
- Sherine F Elsawa
- Department of Biology, University of North Carolina, Charlotte, NC 28223, USA
| | | | | | | | | | | |
Collapse
|
35
|
Joos GF, De Swert KO, Pauwels RA. Airway inflammation and tachykinins: prospects for the development of tachykinin receptor antagonists. Eur J Pharmacol 2001; 429:239-50. [PMID: 11698044 DOI: 10.1016/s0014-2999(01)01323-1] [Citation(s) in RCA: 50] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
Abstract
The tachykinins substance P and neurokinin A are contained within sensory airway nerves. Immune cells form an additional source of tachykinins in inflamed airways. Elevated levels of tachykinins have been recovered from the airways of patients with asthma and chronic obstructive pulmonary disease. Airway inflammation leads to an upregulation of tachykinin NK(1) and NK(2) receptors. Preclinical studies have indicated a role for the tachykinin NK(1), NK(2) and NK(3) receptors in bronchoconstriction, airway hyperresponsiveness and airway inflammation caused by allergic and nonallergic stimuli. Compounds that are able to block two or three tachykinin receptors hold promise for the treatment of airways diseases such as asthma and/or chronic obstructive pulmonary disease.
Collapse
Affiliation(s)
- G F Joos
- Department of Respiratory Diseases, Ghent University Hospital, De Pintelaan 185, B-9000 Ghent, Belgium.
| | | | | |
Collapse
|